Sudeep Pharma Recommends ₹1.50 Dividend for FY26

Sudeep Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the year ended March 31, 2026. They recommended a final dividend of ₹1.50 (150%) per equity share of ₹1 each, subject to shareholder approval. The board also approved the appointment of M/s. Chetan Gandhi & Associates as Cost Auditor for FY 2026-27 and M/s H M Mehta & Associates as Secretarial Auditor for five years from the conclusion of the 37th AGM until the 41st AGM.